Whereas experience is growing rapidly with the use of ferumoxytol as an alternative to gadolinium based contrast agents (GBCA) for cardiovascular imaging, little has been reported about its potential for imaging of solid organs. The pharmacokinetics and relaxometry of ferumoxytol are very different to all of the available GBCA, and data are lacking about its behavior in extracranial solid organ lesions. We report early results of FE-MR imaging in a variety of solid organ mass lesions with focus on enhancement characteristics and clinical impact.
This abstract and the presentation materials are available to members only; a login is required.